KPC(SH:600422)2019-04-26 16:00Financial Performance - Net profit attributable to shareholders increased by 25.32% to CNY 103,083,732.50 year-on-year[12] - Operating revenue rose by 8.24% to CNY 1,777,702,273.34 compared to the same period last year[12] - Basic earnings per share increased by 29.03% to CNY 0.1360[12] - The weighted average return on net assets increased by 0.44 percentage points to 2.66%[12] - Total operating revenue for Q1 2019 was ¥1,777,702,273.34, an increase of 8.2% compared to ¥1,642,369,522.37 in Q1 2018[44] - Net profit for Q1 2019 reached ¥104,661,285.51, representing a 26% increase from ¥83,165,785.77 in Q1 2018[47] - Total profit for Q1 2019 was ¥126,047,415.68, up from ¥101,139,464.82 in Q1 2018, reflecting a growth of 24.6%[47] - Total comprehensive income increased to ¥61,518,982.30 from ¥49,503,653.66, representing a growth of approximately 24.5% year-over-year[52] Assets and Liabilities - Total assets increased by 4.95% to CNY 7,232,478,864.38 compared to the end of the previous year[12] - Total assets increased to ¥7,232,478,864.38 from ¥6,891,613,423.84, reflecting growth in both current and non-current assets[33] - Total liabilities rose to ¥3,179,903,322.18, compared to ¥2,943,112,952.49, indicating an increase of about 8.0%[39] - Shareholders' equity reached ¥4,052,575,542.20, up from ¥3,948,500,471.35, reflecting a growth of approximately 2.6%[39] - Total current liabilities rose to ¥1,316,538,030.64 from ¥941,737,688.08, indicating an increase of approximately 40.0%[42] - The total assets of the company were RMB 4,621,789,072.07, showcasing overall growth in asset base[77] Cash Flow - Net cash flow from operating activities improved by 31.82%, reaching CNY -107,926,400.96[12] - Operating cash flow improved by 31.82% to -¥107,926,400.96 from -¥158,289,792.91, due to better management of receivables[24] - Cash inflow from operating activities totaled ¥1,884,570,019.70, up from ¥1,629,198,663.05, indicating an increase of about 15.6%[52] - Total cash outflow from operating activities was ¥1,992,496,420.66, compared to ¥1,787,488,455.96, reflecting an increase of about 11.4%[56] - Cash inflow from investment activities reached ¥1,051,355,186.84, compared to ¥893,735,884.40, marking an increase of approximately 17.7%[56] - The ending cash and cash equivalents balance decreased to ¥464,489,869.54 from ¥797,068,946.93, a decline of about 41.8%[58] Shareholder Information - The total number of shareholders at the end of the reporting period was 54,771[19] - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 30.81% of the shares[19] - The company plans to repurchase shares worth ¥50 million to ¥200 million to align stock price with intrinsic value[25] - The company has repurchased 1,174,200 shares, accounting for 0.154% of total share capital, at an average price between ¥6.20 and ¥7.57 per share[25] Research and Development - Research and development expenses decreased by 30.95% to ¥13,538,668.86 from ¥19,607,150.14, indicating reduced capitalized R&D spending[22] - Research and development expenses decreased to ¥13,538,668.86 in Q1 2019 from ¥19,607,150.14 in Q1 2018, a reduction of 30.9%[44] Other Financial Metrics - Government subsidies recognized in the current period amounted to CNY 27,884,135.32[14] - The company reported a non-operating income of CNY 23,421,680.37 for the current period[16] - Other income for Q1 2019 was ¥27,884,135.32, an increase from ¥15,294,194.90 in Q1 2018, showing an increase of 82.5%[44] - The company reported a significant increase in accounts receivable, totaling $1.35 billion, indicating strong sales performance[65] - The company has a deferred income of RMB 85,136,743.63, indicating future revenue recognition[77]